Compass Pathways PLC Sponsored ADR $CMPS Shares Newly Purchased by Pekin Hardy Strauss Inc.

Posted by Brian Himes on Nov 7th, 2026

Pekin Hardy Strauss Inc. acquired a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report) in the third quarter, Holdings Channel.com reports. The firm acquired 63,650 shares of the company’s stock, valued at approximately $792,000.

A number of other large investors also recently modified their holdings of the company. Vivo Capital LLC bought a new stake in Compass Pathways during the 1st quarter worth approximately $1,106,000. Seven Fleet Capital Management LP lifted its stake in Compass Pathways by 295.1% in the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after purchasing an additional 118,021 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in Compass Pathways in the 1st quarter worth approximately $6,363,000. Eversept Partners LP bought a new position in Compass Pathways in the 1st quarter valued at $3,749,000. Finally, Eagle Health Investments LP grew its position in shares of Compass Pathways by 35.6% during the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock valued at $11,394,000 after purchasing an additional 541,039 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Price Performance

Shares of Compass Pathways stock traded up $0.80 during trading on Friday, hitting $8.61. 3,757,104 shares of the stock traded hands, compared to its average volume of 3,011,761. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43. The firm’s fifty day moving average is $12.32 and its 200-day moving average is $10.41. Compass Pathways PLC Sponsored ADR has a 52 week low of $4.88 and a 52 week high of $15.87.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Research analysts expect that Compass Pathways PLC Sponsored ADR will post -0.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Jefferies Financial Group restated a “buy” rating on shares of Compass Pathways in a research note on Wednesday, September 9th. BTIG Research reiterated a “buy” rating and set a $25.00 price target on shares of Compass Pathways in a research report on Tuesday. B. Riley Financial lifted their price target on Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Thursday, October 15th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Compass Pathways in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.14.

Check Out Our Latest Stock Report on CMPS

Compass Pathways Company Profile

(Free Report)

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.